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Abstract
The EBNA1 protein of Epstein-Barr virus (EBV) plays essential roles in enabling the replication and persistence of EBV
genomes in latently infected cells and activating EBV latent gene expression, in all cases by binding to specific recognition
sites in the latent origin of replication, oriP. Here we show that EBNA1 binding to its recognition sites in vitro is greatly
stimulated by binding to the cellular deubiquitylating enzyme, USP7, and that USP7 can form a ternary complex with DNA-
bound EBNA1. Consistent with the in vitro effects, the assembly of EBNA1 on oriP elements in human cells was decreased by
USP7 silencing, whereas assembly of an EBNA1 mutant defective in USP7 binding was unaffected. USP7 affinity column
profiling identified a complex between USP7 and human GMP synthetase (GMPS), which was shown to stimulate the ability
of USP7 to cleave monoubiquitin from histone H2B in vitro. Accordingly, silencing of USP7 in human cells resulted in a
consistent increase in the level of monoubquitylated H2B. The USP7-GMPS complex formed a quaternary complex with
DNA-bound EBNA1 in vitro and, in EBV infected cells, was preferentially detected at the oriP functional element, FR, along
with EBNA1. Down-regulation of USP7 reduced the level of GMPS at the FR, increased the level of monoubiquitylated H2B in
this region of the origin and decreased the ability of EBNA1, but not an EBNA1 USP7-binding mutant, to activate
transcription from the FR. The results indicate that USP7 can stimulate EBNA1-DNA interactions and that EBNA1 can alter
histone modification at oriP through recruitment of USP7.
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Introduction
Epstein-Barr virus (EBV) is a gamma herpesvirus that infects
over ninety percent of people worldwide. As part of its latent life
cycle, EBV efficiently immortalizes the host cell and predisposes it
to a number of malignancies, including Burkitt’s lymphoma,
nasopharyngeal carcinoma, gastric carcinoma, Hodgkin’s disease
and a variety of lymphomas in immunosuppressed patients [1]. In
latently infected cells, replication and maintenance of the viral
genome require the latent origin of replication, oriP and the
EBNA1 protein. OriP is comprised of two functional elements, the
dyad symmetry (DS) and the family of repeats (FR), which contain
four and twenty copies of an 18 bp palindromic EBNA1 binding
site respectively [2,3]. Replication of oriP-containing plasmids
requires EBNA1 binding to the DS [4]. EBNA1 binding to the FR
is required for the mitotic segregation of the oriP-containing
plasmids and transactivation of several latency genes [5,6].
EBNA1 binds DNA through residues 459–607, which form the
DNA binding and dimerization domain (EBNA1-DBD) [7–9].
High resolution structures of the EBNA1-DBD, alone and in
complex with its DNA binding site, have revealed details of the
interaction of EBNA1 with DNA [10–12]. EBNA1-DBD com-
prises two subdomains: residues 504–604, referred to as the core-
domain, and residues 461–503, referred to as the flanking domain.
The core domain is a b-barrel structure that forms the
dimerization interface and makes transient sequence-specific
contacts with the DNA through an a-helix [10,13]. The flanking
domain consists of an a-helix (residues 477–489) oriented
perpendicular to the axis of the DNA, which contacts the major
groove through Lys 477, and an extended chain (amino acids 461–
469) that runs along the base of the minor groove of the DNA,
making sequence-specific contacts through Lys-461, Gly-463 and
Arg-469 [11].
In addition to binding specific DNA sequences, EBNA1 is also
known to interact with several host-cell proteins, which in some
cases have been shown to mediate EBNA1 functions at oriP
[14–18]. EBNA1 can also affect cellular processes through
sequestration of cellular proteins, as best exemplified by the
EBNA1 interaction with the ubiquitin specific protease USP7, also
referred to as Herpesvirus Associated Ubiquitin Specific Protease
(HAUSP). USP7 was originally identified as a binding partner of
the ICP0 protein of herpes simplex virus (HSV) [19] and, since
then, several cellular targets of USP7 have been identified
including the p53 tumour suppressor protein [20–24]. In response
to genotoxic stress, USP7 binds and deubiquitylates p53 thereby
protecting it from proteasome-mediated degradation. In addition
to cleaving polyubiquitin chains, USP7 has been reported to
reverse monoubiquitylation in some proteins (eg. p53 and
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Similarly, the Drosophila homologue of USP7 was found to
contribute to epigenetic silencing by reversing monoubiquitylation
of histone H2B, and this activity required USP7 to be in complex
with guanosine 59 monophosphate synthetase (GMPS) [27].
Our studies on the EBNA1-USP7 interaction have shown that
EBNA1 binds the N-terminal domain of USP7 (USP7-NTD),
which is distinct from the catalytic domain, and is the the same
domain that is bound by p53 [28]. EBNA1 and p53 bind the same
pocket in this domain but EBNA1 does so with an affinity that is
approximately 10-fold higher than that of p53 [28,29]. As a result,
EBNA1 interferes with the binding and stabilization of p53 by
USP7 and with p53-mediated apoptosis in response to DNA
damage [29,30]. In addition, we recently found that EBNA1
disrupts promyelocytic leukemia (PML) nuclear bodies (also called
ND10s) in nasopharyngeal carcinoma cells by inducing the
degradation of the PML proteins [30]. This activity required
USP7 and the EBNA1-USP7 interaction, indicating that this
interaction can modulate cellular events in addition to p53 levels.
EBNA1 deletion analysis showed that the USP7 binding
sequence in EBNA1 was just N-terminal to the flanking DNA
binding domain and subsequent peptide binding assays identified
EBNA1 residues 436–450 as sufficient for this interaction [28,29]. A
crystal structure of an EBNA1 peptide bound to the USP7-NTD
revealed multiple interactions of EBNA1 residues 442–448 with
amino acidsina shallowgrooveoftheTRAFdomainformed bythe
USP7-NTD [29]. In particular interactions mediated by Ser447 in
EBNA1 wereshown tobe critical forUSP7 binding. Given thelarge
size of USP7 (135 kDa) and the proximity of its binding site to the
EBNA1-DBD residues that are inserted in the DNA minor groove
(amino acids 461–469), we wondered whether the USP7 interaction
interfered with EBNA1 binding to DNA. Here we report that,
contrary to our expectations,USP7 had a largestimulatory effecton
the DNA-binding activity of EBNA1 in vitro and can form a ternary
complex with DNA-bound EBNA1. Furthermore, USP7 was found
to bind GMPS, forming a complex active in histone H2B
deubiquitylation, and this complex was recruited to oriP in EBV-
infected cells resulting in decreased H2B ubiquitylation.
Results
Effect of USP7 on DNA binding by EBNA1 in vitro
We initially assessed the effect of USP7 on the DNA binding
activity of EBNA1 using electrophoretic mobility shift assays
(EMSAs) with a version of EBNA1 that has a shortened Gly-Ala
repeat but has wildtype activity for all known EBNA1 functions
(referred to as EBNA1; Figure 1A). Purified EBNA1 was incubated
with radiolabelled DNA containing a single EBNA1 recognition site
(site 1 from the DS element) in presence and absence of excess
purified full length USP7. We consistently observed that USP7
stimulated the DNA binding activity of EBNA1 as shown in the
representative experiment inFigure1B (left panel),while no obvious
effects on EBNA1-DNA interactions were seen with nonspecific
proteins such as BSA (Figure 1B, right panel). Results from multiple
experiments showed a 20-fold increase in the DNA binding affinity
of EBNA1 in the presence of USP7, resulting in a shift in the
dissociation constant (Kd) from 8567nM for EBNA1 alone to
4.360.4 nM for EBNA1 in presence of USP7. This increase in
DNA binding affinity was largely dependant on the ability of
EBNA1 to bind USP7, as the DNA binding ability of a truncation
mutant of EBNA1 (EBNA1452–641) containing the DNA-binding
and dimerization region but lacking the USP7 binding site was
muchlessaffected by USP7 (onaverage showinga 4-fold increase in
DNA binding in the presence of USP7; Figure 1C).
EBNA1 dimers bound to DNA are known to interact with each
other resulting in the crosslinking of multiple DNA fragments
through large EBNA1 complexes (referred to as looping or linking
interactions) [31–33]. These complexes are retained in the wells of
the gel in EMSAs as shown in Figure 1B, precluding analysis of the
effect of USP7 on the migration of the DNA complexes. The linking
interactions of EBNA1 are mediated largely by amino acids 325–
376 and to a lesser degree by EBNA1 N-terminal residues [32,34].
To further evaluate the effect of USP7 on the DNA binding ability
of EBNA1 without the confounding effects of DNA linking, we
repeated the EMSAs with the EBNA1 truncation mutant 395–641
(Figure 1A), which contains the USP7 binding site and the DNA-
binding region but lacks sequences that cause DNA linking. When
the DNA binding affinity of EBNA1395–641 was measured in the
presence and absence of excess USP7, USP7 was consistently found
to stimulate DNA binding by EBNA1395–641 (Figure 2A, left panel),
resulting in a 50-fold decrease in the calculated Kd from
233676 nM for EBNA1395–641 alone to 461.8 nM for
EBNA1395–641 in presence of USP7. This experiment also showed
that the bound DNA migrated more slowly in the presence of
EBNA1395–641 and USP7 than with EBNA1395–641 alone, suggest-
ing that USP7 formed a ternary complex with EBNA1395–641 and
DNA.
Since EBNA1 is known to bind to the N-terminal TRAF
domain of USP7 (USP7-NTD) [28,29], we examined whether this
domain was sufficient to stimulate EBNA1395–641 binding to DNA.
When EBNA1395–641 titrations were performed in the presence of
excess USP7-NTD, the DNA binding activity was increased 8 to
16-fold in multiple experiments, (Figure 2A, right panel) indicating
that the USP7-NTD was partially, but not completely, responsible
for the stimulatory effect of USP7 on EBNA1 DNA binding
activity. Consistent with the USP7 result, the USP-NTD was
found to decrease the migration of the EBNA1-bound DNA
suggesting that it can bind the EBNA1-DNA complex.
We also examined the stimulatory effect of USP7 on DNA
binding by EBNA1395–641 by incubating a fixed amount of
EBNA1395–641 (sufficient to bind a small fraction of the DNA
probe on its own) with increasing amounts of USP7 prior to the
addition of the DNA binding site Figure 2B, left panel). EMSAs
performed in this way showed that USP7 had a dose-dependent
effect on the DNA binding activity of EBNA1395–641. The
possibility that USP7 itself had some ability to bind the DNA
probe was tested by titrating USP7 with the DNA in the absence of
any EBNA1, but USP7 alone did not shift the DNA probe even at
very high concentrations of USP7 (Figure 2B, right panel lanes 8–
12). Similarly, the USP7-NTD on its own did not bind the DNA-
probe (Figure 2B, right panel lanes 1–7).
Author Summary
Epstein-Barr virus (EBV) infections persist for the lifetime of
the host largely due to the actions of the EBNA1 viral
protein. EBNA1 enables the replication and stable persis-
tence of EBV genomes and activates the expression of
other EBV genes by binding to specific DNA sequences in
the EBV genome. We have shown that the cellular protein
USP7 stimulates EBNA1 binding to its DNA sequences and
that EBNA1 recruits USP7 to the EBV genome, which in
turn recruits another cellular protein GMP synthetase. The
complex of USP7 and GMP synthetase then functions to
alter the chromatin structure at a region of the EBV
genome that controls EBV persistence. These changes to
the EBV genome are likely important for enabling the
persistence of EBV genomes in infected cells.
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the EBNA1-DNA complex resulting in a supershift while the
titration performed with lesser amounts of USP7 in Figure 2B did
not show a supershift. To investigate this discrepancy, we
preformed EBNA1-DNA complexes (using EBNA1395–641 as
above) then added increasing amount of USP7 (Figure 2C).
EMSAs confirmed that USP7 was able to supershift the
EBNA1395–641-DNA complex but only at higher concentrations
of USP7 (compare lanes 6 and 7 to lanes 2–5). To confirm that the
supershifted band contained EBNA1, complexes formed as in
lanes 2 and 7 were incubated with an EBNA1-specfic antibody
prior to electrophoresis. In both cases the antibody supershifted
the bands to the gel wells, whereas no effect of the antibody was
seen on the migration of the DNA probe in the absence of EBNA1
(Figure 2C, lanes 8–10). The results indicate that USP7 can form
a ternary complex with DNA-bound EBNA1 under some
conditions.
Effects of USP7 silencing on EBNA1-DNA interactions in vivo
During initial EBV infection, EBNA1 assembles on its
recognition sites in oriP and remains stably bound to these sites
in all types of latently infected cell lines. Therefore it was not
possible to determine the effects of USP7 on EBNA1 assembly on
oriP using latently infected cells. Instead, we assessed the effect of
USP7 on the initial association of EBNA1 with oriP by treating
EBV-negative nasopharyngeal carcinoma cells (CNE2Z) with
siRNA against USP7 or GFP (negative control) and then
transfecting these cells with an oriP plasmid expressing EBNA1
or an EBNA1 mutant (D395–450; see Figure 1A) that we
previously showed was specifically defective in binding USP7
[14] and a plasmid lacking EBNA1 binding sites (pLacZ) as control
for nonspecific DNA binding. Chromatin immunoprecipitation
(ChIP) assays were then performed using EBNA1-specific
antibodies to assess the degree of EBNA1 association with the
the oriP FR and DS elements and lacZ (negative control) as
Figure 1. EBNA1 binding to DNA is stimulated by USP7. A. Schematic representation of EBNA1 and the EBNA1 mutants used in this study.
Shown are the Gly-Ala repeat (GA), the large Gly-Arg repeat (GR), the USP7 binding site (USP7) and the flanking and core DNA binding domains. B
and C. EMSAs showing titrations of EBNA1 (B) or EBNA1452–641 (C) with a fixed amount of DNA recognition site in the presence or absence of
10 pmols of USP7 or in the presence or absence of 10 pmols BSA as a negative control (B, right panel).
doi:10.1371/journal.ppat.1000624.g001
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PLoS Pathogens | www.plospathogens.org 3 October 2009 | Volume 5 | Issue 10 | e1000624Figure 2. Analyses of the USP7 effect on DNA interactions of EBNA395–641.A .EMSAs showing titrations of EBNA395–641 with a fixed amount
of DNA recognition site in the presence or absence of 10 pmols of USP7 (left panel) or USP7-NTD (right panel). B. EMSAs performed with a fixed
amount of EBNA395–641 and DNA and the indicated amounts of USP7 (left panel). Titrations of USP7 and the USP7-NTD with DNA in the absence of
EBNA1 are shown in the right panel. C. Complexes of EBNA395–641 and DNA were preformed then incubated with the indicated increasing amounts of
USP7. Complexes formed as in lanes 1,2 and 7 were then incubated with anti-EBNA1 antibody (R4) prior to polyacrylamide gel electrophoresis.
doi:10.1371/journal.ppat.1000624.g002
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on both the DS and FR elements after siGFP treatment but the
association with both elements was greatly decreased by USP7
silencing (Figure 3A, middle panels). As expected, there was little
association of EBNA1 with lacZ and this was unaffected by USP7
silencing (right panel). Consistent with the in vitro results, D395–
450 bound less efficiently to both the DS and FR elements than
did wildtype EBNA1, despite being expressed at equivalent levels
as EBNA1 (see Figure 3A, left panel). Moreover, unlike wildtype
EBNA1, the interaction of D395–450 with the FR and DS
elements was not affected by USP7 silencing. Therefore we
conclude that USP7 can stimulate the assembly of EBNA1 on oriP
elements in vivo.
In addition to binding the oriP elements, EBNA1 can interact in
a more transient manner with a third region of the EBV genome
(referred to as region III), consisting of two lower affinity EBNA1
recognition sites within the BamHI-Q fragment, and this
interaction can negatively regulate the Qp promoter used for
EBNA1 expression in some types of EBV latency [3,35,36]. Due to
the transient nature of the EBNA1 interaction with region III, we
asked whether USP7 might promote the EBNA1-region III
interaction in latently infected cells. D98/Raji cells were used
for these experiments since these EBV-infected cells are more
transfectable than the Raji cells from which they were derived.
D98/Raji cells were transfected with siRNA against USP7 or GFP
then ChIP experiments were performed using EBNA1-specific
antibody and primer sets for region III. While we did not achieve
complete silencing of USP7 in these experiments (Figure 3B, left
panel), its down-regulation was consistently found to decrease the
association of EBNA1 with region III (Figure 3B, right panel),
indicating that USP7 can also modulate EBNA1-DNA interac-
tions in the context of an EBV infection.
USP7 is recruited to EBV oriP
The above inv i t r oanalyses raised the possibility that EBNA1 may
recruit USP7 to oriP in EBV-infected cells. To test this possibility we
conducted ChIP experiments in EBV-positive B-lymphocytes (Raji
cells). Antibodies against EBNA1 or USP7 were used to immuno-
precipitate these proteins from sheared Raji DNA and compared to
non-specific rabbit IgG as a negative control. Immunoprecipitates
were analyzed by quantitative real-time PCR using primers specific
for the DS and FR regions in oriP and for the promoter region of the
BZLF gene, located 40 kb away from oriP. EBNA1 is known to be
constitutively bound to the FR and DS elements [37,38] and,
consistent with this, was readily detected on both the FR and DS
DNA fragments (with better recovery of the DS element as has been
previously observed;[16,39,40]) but was not detected on the BZLF1
fragment (Figure 4A). The USP7 antibody consistently isolated more
FR DNA fragment than either the DS or BZLF1 fragments
(Figure 4A). Recovery of the FR region (but not the DS region)
was significantly higher than that of the BZLF1 region with a p-value
of 0.0004. The results indicate that USP7 is preferentially recruited to
FR and is consistent with the higher enrichment of EBNA1 at the FR.
USP7 forms a complex with GMP synthetase that
deubiquitylates histone H2B
USP7 is known to regulate p53 levels but this would not seem to
explain why it is recruited to oriP. To gain insight into other
potential functions of USP7, we used a proteomics approach to
identify cellular protein partners of USP7. To this end, increasing
Figure 3. Effects of USP7 silencing on EBNA1-DNA interactions in vivo. A. CNE2Z cells were treated with siRNA against USP7 or GFP then co-
transfected with pLacZ and with an oriP plasmid expressing EBNA1 or D395–450 as indicated or empty oriP plasmid (oriP). Equal amounts of cell
lysates were analysed for protein expression by Western blotting (left panel) and ChIP assays were performed with EBNA1 and nonspecific antibodies
for the DS and FR elements of oriP and for the lacZ gene. Results are shown after normalization to nonspecific IgG and input DNA. B. D98/Raji cells
were transfected with siRNA against USP7 or GFP then ChIP assays were performed with EBNA1 antibodies and nonspecific antibodies (IgG) and a
primer set near region III. Changes with P values less than 0.01 (**) and less than 0.05 (*) relative to siGFP samples are indicated.
doi:10.1371/journal.ppat.1000624.g003
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of USP7 affinity columns and a constant amount of human cell
extract was passed through each column. Proteins retained on the
columns were eluted with 1 M NaCl, followed by 1% SDS, and
the recovered proteins were analysed by SDS-PAGE and silver
staining (Figure 5A). Only 1 band (at approximately 70 Kda) was
observed to be specifically retained on the USP7 column, showing
a titratable interaction with USP7 as expected for a specific protein
interaction, and this was identified by MALDI-ToF mass
spectrometry as GMP synthetase (GMPS).
The interaction between USP7 and GMPS was further
examined by glycerol gradient sedimentation analysis of the
purified proteins. For these experiments, GMPS, like USP7, was
generated using a baculovirus and extensively purified. Analysis of
the individual proteins by glycerol gradient sedimentation showed
that USP7 migrates close to its calculated molecular mass of
130 Kd indicating that it is monomeric (Figure 5B, top panel).
This is consistent with previous analytical centrifugation analyses
[28]. GMPS was found to migrate at a similar position as USP7
despite its smaller molecular mass of 77 Kda suggesting that it
forms dimers (Figure 5B, middle panel), as occurs for E.coli GMPS
[41]. When USP7 and GMPS were combined, their positions in
the gradient shifted to a higher molecular weight form, confirming
that the two proteins directly interact (Figure 5B, bottom panel).
The size of this complex (approximately 200 Kda) suggested that it
consisted of one USP7 and one GMPS molecule.
A previous study reported that Drosophila USP7 formed a
complex with GMPS in Drosophila embryos and that this complex
deubiquitylated histone H2B thereby contributing to polycomb-
mediated silencing [27]. This prompted us to investigate whether
the human USP7-GMPS complex also functioned to deubiquity-
late histone H2B. To this end, we purified total histones from
Figure 4. Chromatin IP assays for USP7, GMPS and Ub-H2B in EBV genomes. A. ChIP experiments were performed in Raji cells using
antibodies against EBNA1 (left panel), USP7 (middle panel), GMPS (right panel) and nonspecific rabbit IgG as a negative control. Recovered DNA
fragments were quantified by real-time PCR using primer sets for the oriP DS and FR regions or the BZLF1 promoter region. B. D98/Raji cells were
treated with siRNA against USP7 or GFP (negative control), then ChIP experiments were performed as in A using antibodies against GMPS (right
panel). Down-regulation of USP7 by siUSP7 treatment was confirmed by Western blotting, while GMPS levels were unaffected by this treatment (left
panel). C. D98/Raji cells were treated with siRNA against USP7 or GFP and ChIP assays were performed using antibodies against histone H2B and
monoubiquitylated histone H2B (Ub-H2B) and primer sets for the indicated region of the EBV genome (LMP=LMP1 promoter region). Relative ratios
of Ub-H2B to total H2B were determined for each treatment and the average fold increase in Ub-H2B after siUSP7 treatment (as compared to siGFP
treatment) from multiple experiments is shown.
doi:10.1371/journal.ppat.1000624.g004
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purified USP7 (at a MW ratio of USP7:histones of 1:1000) for
various times prior to Western blot analysis. Histone H2B and its
monoubiquitylated form (Ub-H2B) were initially detected using an
antibody specific to histone H2B, and USP7 was found to have
some ability to deubiquitylate H2B on its own (Figure 6A, left
panel). Histone H2A and its monoubiquitylated form were
detected in the same assay with antibody specific to H2A,
however, in contrast to the H2B results, USP7 was not observed to
deubiquitylate H2A (Figure 6A, right panel).
To determine if GMPS affected the ability of USP7 to
deubiquitylate H2B, we repeated the experiments including different
amounts of GMPS (Figure 6B). The Ub-H2B was more readily
detected using an anti-ubiquitin antibody, providing a more robust
signal to follow and this band is shown in Figure 6B. We found that
the addition of GMPS at amounts stoichiometric to USP7 increased
t h ec l e a v a g eo fU b - H 2 Bb yU S P 7a te a c ht i m ep o i n te x a m i n e d
(compare ‘‘1:1’’ samples to ‘‘USP7’’ samples within each panel).
Increasing the amount of GMPS 10-fold had no further stimulatory
effect (compare ‘‘1:10’’ samples to ‘‘1:1’’ samples in the left panel),
while decreasing the amount of GMPS 10-fold abrogated the
stimulatory effect (compare ‘‘10:1’’ samples to ‘‘1:1’’ samples in the
right panel). These results are consistent with GMPS stimulating
deubiquitylation of H2B by USP7 by forming a stoichiometric
complex with USP7 and are inconsistent with GMPS acting
catalytically. We also asked whether the stimulatory activity of
GMPS was specific to H2B deubiquitylation or also occurred for
other USP7 targets. To this end, we incubated USP7, with or without
equal amounts of GMPS, with p53 that had been polyubiquitylated in
vitro and we followed the p53 forms by Western blotting with a p53
antibody (Figure 6C). In this case, we saw no obvious difference in the
kinetics of cleavage of the ubiquitylated forms by USP7 with or
without GMPS, indicating that GMPS does not affect all USP7
targets equally and rather has specificity for Ub-H2B.
To assess whether USP7 regulates histones in human cells, we
down-regulated USP7 in HeLa cells with siRNA treatment then
prepared total histones as for the in vitro assays. The ratio of
monoubiquitylated to nonmodified forms of H2A and H2B were
then determined by Western blotting using antibodies against H2A
and H2B. An example of the results obtained is shown in the gel
imagesinFigure6Dascomparedtoresultswiththesamecellstreated
with siGFP as a negative control. We consistently observed an
increase in the ratio of Ub-H2B to total H2B after USP7 silencing, as
compared to GFP silencing (negative control), but we did not see a
reproducible effect on the H2A monubiquitylated form. Results from
three independent experiments are shown in histogram in Figure 6D.
Therefore the in vivo studies support the conclusions of the in vitro
results, that USP7 can regulate H2B monoubiquitylation.
Formation of a DNA-EBNA1-USP7-GMPS quaternary
complex
We next investigated the relevance of the USP7-GMPS
interaction for EBNA1, in particular whether GMPS could form
part of the USP7-EBNA1-DNA complex. We examined this in
two ways: First, we tested possible interactions between DNA-
bound EBNA1395–641 with GMPS with and without USP7 by
EMSAs (Figure 7). The binding of EBNA1395–641 to the DNA
probe was assessed on its own or after incubation of the same
amount of EBNA1 with USP7 or GMPS and the migration of the
DNA complexes was assessed. As observed above, USP7 shifted
the EBNA1-DNA complex to a slower migrating form indicative
of a ternary complex (Figure 7, compare lanes 2 and 3). On the
other hand, the same amount of GMPS did not alter the mobility
of the EBNA1-DNA complexes (Figure 7, compare lanes 2 and 4).
Figure 5. USP7 forms a complex with GMPS. A. Purified USP7 was
coupled to a fixed amount of resin at the indicated concentrations to
generate a series of affinity columns. A constant amount of HeLa whole
cell lysate was applied to each, followed by washing then elution of the
bound proteins with 1 M NaCl then with 1% SDS. A silver-stained gel is
shown in which the band marked by the arrow was excised and
identified as GMPS by MALDI-ToF mass spectrometry. The band at
120 kDa in the 1% SDS elution is USP7 itself. B. Purified USP7 and GMPS
were analysed by glycerol gradient sedimentation individually (top and
middle panels) and after mixing the two proteins (bottom panel). Equal
volume fractions were collected from the top of each gradient and
analysed by SDS-PAGE and colloidal Coomassie staining. The positions
of 158 kDa (aldolase) and 232 kDa (catalase) molecular weight markers
are indicated at the top of the gels.
doi:10.1371/journal.ppat.1000624.g005
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between EBNA1 and GMPS. However, when USP7, GMPS and
EBNA1 were combined (the same amounts as when tested
individually), and then added to the DNA, these complexes shifted
to a position higher than that of the USP7-EBNA-DNA ternary
complex as shown in lanes 5 and 6 of Figure 7 (compare to lane 3).
However neither GMPS, USP7 nor GMPS+USP7 interacted with
the DNA in the absence of EBNA1 (Figure 7, lanes 8–10). The
results suggest that USP7 mediates an interaction between GMPS
and the EBNA1-DNA complex resulting in the formation of a
quaternary complex.
We also examined the possible association between USP7-
GMPS complexes and EBNA1 in vivo, by determining if GMPS
localized with EBNA1 and USP7 on EBV chromatin. ChIP
experiments performed on Raji cells, showed that, like USP7,
GMPS was preferentially detected at the FR element of oriP over
the DS element or the BZLF1 region (Figure 4A, right panel). This
is consistent with the recruitment of the USP7-GMPS complex to
the FR through EBNA1.
We next investigated whether recruitment of GMPS to the FR
was dependent on USP7, as suggested by the EMSA experiments.
These experiments required down-regulation of USP7 by siRNA
treatment and could not be performed in Raji cells due to their low
transfection efficiency. Instead, the more readily transfectable
D98/Raji fusion cells were used, which retain the EBV genomes
from Raji cells [42]. USP7 was confirmed to be down-regulated in
these cells following treatment with siRNA against USP7 but not
siRNA against GFP (negative control), while GMPS levels were
Figure 6. GMPS stimulates histone H2B deubiquitylation by
USP7. A. Total histones isolated from HeLa cells were incubated with
USP7 (1:1000 ratio of USP7:histones) for 0, 1, 5 or 30 minutes then
analysed by Western blotting using antibodies against histones H2B
(left panel) or H2A (right panel). The positions of the unmodified (H2B/
H2A) and monoubiquitylated (mUb) histones are indicated. B. Total
histones were incubated with USP7 as in A for the indicated number of
minutes, with (USP7+GMPS) or without (USP7) GMPS, at a ratio of 1:1,
1:10 or 10:1 USP7:GMPS as indicated. Western blot analysis was then
performed using anti-ubiquitin antibody and the band corresponding
to monoubiquitylated H2B in part A is shown. C. Polyubiquitylated p53
was incubated with USP7 for the indicated number of minutes with
(USP7+GMPS) or without (USP7) a 10-fold excess of GMPS. Samples
were analysed by Western blotting using p53 antibody. The positions of
unmodified (p53) and ubiquitylated p53 (Ub-p53) are indicated. D.
HeLa cells were transfected with siRNA against GFP or USP7 and USP7
silencing was confirmed by Western blotting of whole cell extracts as
compared to an actin loading control (top two gel panels). Total
histones were prepared from the siRNA treated cells and Western blots
were performed using antibodies against histones H2B or H2A (bottom
two gel panels). The ratio of the monoubiquitylated to unmodified
forms was determined for H2A and H2B and the results from multiple
experiments are shown in the histogram, in relationship to the ratio
observed with siGFP treatment (set to 1).
doi:10.1371/journal.ppat.1000624.g006
Figure 7. GMPS can form a quaternary complex with USP7,
EBNA1 and DNA. The indicated combinations of EBNA1395–641 , USP7
and GMPS were preincubated then combined with the DNA containing
the EBNA1 recognition site and EMSAs were performed as in Figure 2C.
Excess amounts of USP7 alone or USP7 and GMPS were used relative to
EBNA1395–641. In lane 6, the USP7-EBNA complex was preformed prior to
the addition of GMPS then DNA. The positions of complexes formed by
EBNA1 alone, EBNA1+USP7 and EBNA1+USP7+GMPS are indicated by
arrowheads 1, 2 and 3 respectively. DNA incubated with the same
amounts of GMPS, USP7 or GMPS+USP7 but in the absence of EBNA1
are also shown (lanes 8–10).
doi:10.1371/journal.ppat.1000624.g007
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these cells showed that, as in Raji cells, GMPS was preferentially
localized to the FR region, and that down-regulation of USP7
resulted in decreased levels of GMPS at the FR (P value 0.01
relative to FR-siGFP samples; Figure 4B, right panel).
If the USP7-GMPS complex functions to deubiquitylate histone
H2B, then the loss of this complex from the FR would be expected
to increase the level of Ub-H2B in this region. We investigated this
possibility by performing ChIP experiments with and without
USP7 silencing, using an antibody that recognizes only the
ubiquitylated form of H2B [43]. To control for possible differences
in the number of histones at each region we performed the same
experiment with antibody against total histone H2B and expressed
the Ub-H2B as a ratio of this value. In Figure 4C (left panel) the
change in the fraction of Ub-H2B after USP7 silencing is shown
from multiple experiments (in relation to siGFP treatment). While
we saw considerable variability on the level of Ub-H2B at the
BZLF1 region, we consistently observed that USP7 silencing
resulted in increased levels of Ub-H2B at the FR and had little
effect on Ub-H2B levels at the DS. The results support the model
that USP7 is needed for recruitment of GMPS to the FR and
subsequent deubiquitylation of histone H2B.
Since EBNA1 binding to the FR is known to activate
transcription from the LMP1 and Cp promoters [44,45], we
examined the possibility that the recruitment of the USP7-GMPS
complex to the FR might also affect H2B ubiquitylation at these
promoters. To this end, ChIP was performed on D98/Raji cells
before and after silencing USP7, using antibodies against Ub-H2B
and total H2B. The recovery of the LMP1 and Cp promoter
regions was quantified for each treatment and the change in the
fraction of Ub-H2B after USP7 silencing was determined.
Silencing of USP7 consistently resulted in increased Ub-H2B at
both the LMP1 and Cp promoters, with the strongest effect on the
Cp promoter, whereas H2B ubiquitylation at the oriLyt region of
EBV (negative control) was not affected by USP7 silencing
(Figure 4C, right panel). The results suggest that the USP7-GMPS
complex not only affects H2B ubiquitylation at the FR but also at
promoters controlled by the FR.
USP7 contributes to transcriptional activation by EBNA1
The above observations suggest that EBNA1-mediated recruit-
ment of the GMPS-USP7 complex to the FR may contribute to
transcriptional activation by this element through alteration of Ub-
H2B at the FR and/or promoters under FR control. To test this
possibility, we treated EBV-negative CNE2Z cells with siRNA
against USP7 or GFP then co-transfected them with a reporter
plasmid in which expression of chloramphenical acetyl transferase
(CAT) is under FR control and with a plasmid expressing either
EBNA1,the EBNA1D395–450 mutant that is unable to bindUSP7
or no EBNA1 (oriP plasmid). CAT assays were then performed on
each sample to assess degree of transcriptional activation (Figure 8).
As expected strong transcriptional activation was seen after siGFP
treatment in the presence of EBNA1 but not in its absence and, as
previously reported [14], D395–450 had slightly reduced transcrip-
tional activity. USP7 silencing caused a significant decrease in
transcriptional activation by EBNA1 (P value 0.004) but did not
significantly affect transactivation by D395–450. These results
support themodel that recruitment of the USP7-GMPScomplex by
EBNA1 contributes to EBNA1-mediated transcriptional activation.
Discussion
EBNA1 forms a stable complex with host cell USP7 and this
interaction can promote cell survival, at least in part through
interfering with p53 stabilization by USP7 and through disrupting
PML nuclear bodies [14,28–30]. Here we provide the first
evidence that the EBNA1-USP7 interaction also contributes to
EBNA1 functions at EBV oriP. This study stemmed from the
unexpected observation that USP7 greatly stimulated the DNA
binding activity of EBNA1 in vitro and could form a ternary
complex with DNA-bound EBNA1. EBNA1 appears to be
constitutively bound to oriP elements in latent EBV infections in
proliferating cells [37,38] and, in these cases, the functional
relevance of these observations for oriP-related functions most
likely lies in the ability of USP7 to form a ternary complex with
DNA-bound EBNA1, as verified at the FR element in EBV-
infected cells. In keeping with this hypothesis, we found that USP7
within this complex can mediate an interaction with GMPS which
promotes deubiquitylation of histone H2B and that USP7
contributes to EBNA1-mediated transcriptional activation. How-
ever we have also shown that USP7 can stimulate the assembly of
EBNA1 on oriP elements in transfected plasmids suggesting that
USP7 might play a role in the initial association of EBNA1 with
these elements upon initial EBV infection, and/or during the
switch from the EBV latency form in nonproliferating cells, in
which EBNA1 is not expressed (referred to as the latency program
[46]), to latency forms in proliferating cells in which EBNA1 is
expressed and bound to oriP. In addition, we have shown that
USP7 can stimulate EBNA1 binding to region III in the EBV
genome which, under some circumstances, negatively regulates
EBNA1 expression [35,36], raising the possibility of a role for
USP7 in EBNA1 autoregulation from the Qp promoter.
We have previously shown that EBNA1 residues 441–450 bind
to the USP7-NTD [28,29]. The ternary complex formed between
USP7 and DNA-bound EBNA1 also appears to require the
interaction of the USP7-NTD with the EBNA1 441–450 region
Figure 8. Effect of USP7 silencing on EBNA1-mediated
transcriptional activation. CNE2Z cells were treated with siRNA
against USP7 or GFP then were co-transfected with an FR-CAT reporter
plasmid and an oriP plasmid expressing EBNA1, D395–450 or no EBNA1
(oriP). CAT assays were then performed on equal amounts of cell lysates
and the percent of acetylated substrate was determined as a measure
of transcriptional activation. Changes with P values less than 0.01 (**)
and less than 0.05 (*) relative to siGFP samples are indicated.
doi:10.1371/journal.ppat.1000624.g008
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to supershift the EBNA1-DNA complex. Second, USP7 did not
supershift the complex formed by DNA and EBNA1452–641, which
lacks the USP7 binding site but retains full DNA binding activity.
However, it is curious that we observed partial but not complete
stimulation of EBNA1 DNA binding by the USP7-NTD. We had
previously assessed the ability of all USP7 stable domains to bind
EBNA1 by examining the retention of partially proteolysed USP7
on an EBNA1 affinity column and only the USP7-NTD was found
to bind EBNA1 [28]. However, this does not eliminate the
possibility that other regions of USP7 might have weak affinities
for EBNA1. Our in vitro data are consistent with a model in which
the USP7-NTD binds EBNA1 residues 441–450 to bring USP7 to
EBNA1, enabling subsequent weaker or less specific interactions of
other regions of USP7 with the EBNA1 DNA binding or C-
terminal regions (452–641). This might explain why the DNA
binding activity of EBNA1452–641 was weakly stimulated by USP7.
Another possible interpretation of the in vitro data is that the
interaction of the USP7-NTD with EBNA1 is stabilized by the rest
of USP7 due to effects on the structure of the USP7-NTD.
However we do not think this is likely because the USP7-NTD is a
TRAF domain that is stably folded in the absence of the rest of
USP7 [29,47].
While stoichiometric amounts of USP7 were sufficient to
stimulate the DNA binding activity of EBNA1, only at higher
USP7 concentrations was USP7 observed to be stably associated
with the EBNA1-DNA complex in vitro. This indicates that the
affinity of USP7 for free EBNA1 is higher than for DNA-bound
EBNA1 and that a higher effective concentration of EBNA1 or
USP7 may be necessary to drive the interaction of these proteins
on DNA. This conclusion is also supported by the observation that
USP7 is preferentially associated with EBNA1 on the FR element
over EBNA1 on the DS element of oriP. The FR element is bound
by 20 EBNA1 dimers as compared to 4 EBNA1 dimers at the DS
element and, in both cases, the dimers within the element interact
with each other to form a larger EBNA1 complex [31,32]. As a
result the effective concentration of EBNA1 at the FR is higher
than at the DS and this may drive recruitment of USP7.
An increasing number of human cellular protein binding targets
of USP7 have been identified including p53, Mdm2, FOXO,
March 7 and PTEN, all of which can be deubiquitylated by USP7
[20–24,26]. Our proteomic profiling of USP7 protein interactions
identified GMPS as another USP7 binding partner. We expect
that other USP7 binding partners were not identified by this
method due to their low abundance or transient nature of the
interaction in response to particular stimuli (such as occurs with
the USP7-p53 and USP7-FOXO interactions). The interaction of
USP7 with GMPS is unique in that it appears to affect the activity
of USP7 for specific substrates, as opposed to being a substrate
itself. This is supported by the fact that GMPS levels are not
altered when USP7 is silenced (as shown in Figure 4B).
The finding that human USP7 forms a stable complex with
GMPS fits well with the observations of van der Knaap et al [27],
where Drosophila USP7 was found to co-purify with GMPS. Our
glycerol gradient sedimentation analyses indicated that human
USP7 and GMPS form a 1:1 complex and in vitro assays show that
GMPS stimulates the ability of USP7 to deubiquitylate H2B (but
not H2A), as observed for the Drosophila GMPS-USP7 complex.
Van der Knapp et al [27] also showed that the stimulation of
Drosophila USP7 activity by GMPS did not require the catalytic
activity of GMPS. Our in vitro results are consistent with this
conclusion because stimulation of USP7 deubiquitylation activity
for H2B required stoichiometric amounts of GMPS (indicative of
formation of a USP7-GMPS complex) and did not occur with
substoichiometric amounts of GMPS (as would be expected for an
enzymatic activity). Although our results are largely in agreement
with those of van der Knaap et al [27], there are subtle differences
in the findings of the two studies. First, Drosophila USP7 was not
found to deubiquitylate H2B in vitro in the absence of GMPS while
we found that human USP7 was able to cleave Ub-H2B in vitro but
that this activity was stimulated by GMPS. Second, In Drosophila,
GMPS was found to stimulate deubiquitylation of p53 by USP7
and we have not observed this effect with human USP7. It is
presently unclear whether these discrepancies are the result of the
different in vitro reaction conditions and protein concentrations or
reflect genuine differences in the Drosophila and human USP7.
ChIP assays consistently showed higher recruitment of USP7
and GMPS to the oriP FR over the DS and the BZLF1 promoter
region, however some degree of interaction of USP7 and GMPS
was also detected at the DS and BZLF1 regions as compared to
the IgG negative control. This may indicate that these proteins are
wide spread on chromatin where they could regulate multiple
processes that are affected by H2B ubiquitylation [48]. H2B
monoubiquitylation has been reported to be associated with
increased transcription through effects on both initiation and
elongation [43,49–51], however in some instances H2B mono-
ubiquitylation appears to inhibit transcription [52–55]. Therefore
the contribution of H2B monoubiquitylation to gene expression is
complicated and possible contributions to other DNA processes
such as DNA replication are largely unexplored. We have
observed that USP7 silencing increases H2B ubiquitylation at
the FR as well as at LMP1 and Cp promoters and decreases
transcriptional activation from the FR element, suggesting that
H2B ubiquitylation is inhibitory to transcription controlled by the
FR. This is consistent with our previous observation that the
EBNA1 mutant that fails to bind USP7 has decreased transcrip-
tional activation function [14].
The increased detection of USP7 and GMPS at the FR element
and their effect on Ub-H2B levels in this region, suggests that
EBNA1 can employ the USP7-GMPS complex for its own
purposes, at least in part by decreasing the level of Ub-H2B. In
addition to functioning in transcriptional activation, the EBNA1-
bound FR element mediates the segregation of the EBV episomes
in mitosis [5,6,16,56], may enhance DNA replication from the DS
[2,57] and causes an impediment to replication fork progression
[4,58,59]. It is conceivable that any of these processes could be
affected by the state of H2B ubiquitylation, since EBV genomes in
latent infection are known to exist as nucleosomal arrays [60]. We
have previously shown that EBNA1D395–450 that does not bind
USP7 has increased DNA replication activity [14], suggesting that
H2B monobiquitylation could promote DNA replication but other
interpretations are also possible.
Histone modifications at oriP are just beginning to be examined
and so far these studies have been focused on histone H3
acetylation and methylation of the oriP DS region. Acetylated
histone H3 is generally enriched at the DS but a decrease was
observed at late G1 that appears to account for the delayed
replication of EBV genomes [61,62]. Histone H3 dimethyl K4 was
also enriched at the DS region while H3 methyl K9 was decreased
at this region [61,63]. Our findings indicate that monoubiquityla-
tion of H2B is another histone modification that is modulated at
oriP and that this modification is affected by EBNA1. We had
previously shown that EBNA1 binding to USP7 serves to alter
cellular processes in order to facilitate cell survival [29,30]. We
now present evidence that the USP7 interaction is not limited to
soluble EBNA1 but also occurs with EBNA1 bound to EBV
episomes where it could regulate the plasmid maintenance and
transcriptional functions of EBNA1 in EBV latent infection.
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EBNA1 purification
EBNA1395–641 was expressed fused to a hexahistidine tag at the
N-terminus in Escherichia coli from plasmid pET15b. This construct
was generated by PCR amplification of EBNA1 sequences
encoding amino acids 395–641 from pc3oriPEBNA1 and ligation
between the Nde1 and BamH1 sites of pET15b. BL21 pLysS cells
containing pET15b- EBNA1395–641 were grown to OD600nm of
0.5 then induced for 3 hrs at 37uC by the addition of IPTG
(0.1 mM final concentration). Cells were lysed in 50 mM
NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole, 20 mM
b-mercaptoethanol, 0.5 mM PMSF, 1 mM benzamidine and
EBNA1395–641 was purified on Ni-NTA Agarose resin (Qiagen)
then dialyzed against 50 mM Tris pH 7.5, 300 mM NaCl,
20 mM b-mercaptoethanol, 1 mM PMSF. EBNA1452–641 was
purified from E.coli as previously described [64]. EBNA1 (lacking
most of the Gly-Ala repeat) was purified from insect cells as
described previously [14].
Purification of USP7 and GMPS
Full length USP7 and USP7-NTD containing amino acids 56–
205 were purified as according to Holowaty et al [14]. GMPS was
expressed in insect cells from a baculovirus. The GMPS
baculovirus was constructed by PCR amplification of full-length
GMPS cDNA in pOTB7 (ATCC number 7515509) using the
primers: GCAGGATCCCATATGGCTCTGTGCAACGGAG-
AC (N-terminus) and GCACTCGAGTTACTCCCACTCAG-
TAGTTCC (C-terminus). The amplification product was digested
with BamHI and XhoI and cloned between the same sites of
pFastBac HT B (invitrogen). Bacmids were obtained by transfor-
mation of competent DH10Bac E. coli (invitrogen) with GMPS
pFastBac HT B, then Spodoptera frugiperda (SF9) insect cells
were transfected with the bacmids to generate the baculovirus
according to manufacturer’s specifications. Culture media con-
taining the baculovirus was harvested 5 days post-transfection and
amplified twice. To generate GMPS for purification, ten 15 cm
plates of High Five cells at 80% confluency were infected with the
GMPS baculovirus. Cells were harvested 50 hrs post-infection,
washed with PBS and lysed in 10 mls of 20 mM Tris-HCl pH 8,
0.5 mM DTT, 0.5 mM EDTA, 10% glycerol and complete
protease inhibitor cocktail (Roche). The lysate was sonicated,
incubated 30 min on ice, then clarified by centrifugation at
64,0006g for 15 min at 4uC. The clarified lysate was incubated
with 250 ml of a nickel resin (Sigma) for 1 h (with rotation) then
transfered to a column. The resin was washed 3 times with 4
column volumes of column buffer (50 mM NaH2PO4, 300 mM
NaCl and 10 mM imidazole) and the His-tagged GMPS was
eluted from the column with column buffer containing 250 mM
imidazole. EDTA and DTT were added to the elutions to a final
concentration of 10 mM and the eluted protein was dialyzed
overnight against 50 mM HEPES pH 7.9, 50 mM NaCl, 10%
glycerol, 0.1 mM EDTA and 0.1 mM DTT then stored in
aliquots at 280uC.
Electrophoretic mobility shift assays (EMSAs)
DNA probes for EBNA1 EMSAs were generated by end-
labeling a 20-mer oligonucleotide corresponding to site 1 of the
DS element (59-CGGGAAGCATATGCTACCCG-39) with c-
32P
-ATP and annealing it to its complementary sequence. In assays
containing EBNA1 and either USP7 or GMPS, EBNA1 was
preincubated with USP7 or GMPS at room temperature (RT) for
10 minutes prior to adding the labeled DNA, except in Figure 2C,
where EBNA1 was incubated with labeled DNA for 10 minutes at
RT first, followed by addition of increasing amounts of USP7 and
further incubation at RT for 10 minutes. In Figures 1 and 2A,
10 pmols of USP7 was used along with the indicated amounts of
EBNA1. For samples containing EBNA1 and both USP7 and
GMPS, USP7 and GMPS were preincubated together at 4uC for
5 minutes before the addition of EBNA1 and further incubation at
RT for 10 minutes. The EMSAs in Figure 7 used 2 pmol EBNA1
dimer and 64 pmols of USP7 and GMPS. Protein mixtures were
incubated with 10 fmoles of labeled DNA at RT for 10 minutes in
the presence of 1 mg salmon sperm DNA in 20 ml binding buffer
(20 mM Tris pH 7.5, 200 mM NaCl). 4 mlo f6 6DNA Loading
Dye (10 mM Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03%
xylene cyanol FF, 60% glycerol, 60 mM EDTA; MBI Fermentas,
R0611) was then added to the reactions prior to electrophoresis
on a 10% polyacrylamide gel. Bands were visualized by
autoradiography.
USP7 affinity column
Purified USP7 was covalently coupled to Affi-Gel 10 (Bio-Rad)
at concentrations of 0, 0.5, 1 or 2 mgs per ml of resin in 50 mM
HEPES pH 7.5, 50 mM NaCl, 1 mM DTT, 5% glycerol. The
resin was then blocked in ethanolamine, equilibrated in column
buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT,
0.1 mM EDTA, 10% glycerol) and used to generate 40 ml
microcolumns as previously described [14,65]. Whole HeLa cell
lysates were generated as in Holowaty et al [14] and equal
amounts were applied to each microcolumn. The columns were
washed in column buffer then sequentially eluted in column buffer
containing 1 M NaCl then the same buffer containing 1% SDS.
Column eluates were analysed by SDS-PAGE and silver staining.
The band running at 70 kDa was excised and prepared for
MALDI-ToF mass spectrometry analysis as previously described
[14]. Recovered peptides were analysed on a Voyager DE-STR
instrument (Applied Biosystems) and the protein was identified by
mass fingerprinting using ProFound software.
Glycerol gradient analysis
50 mg of purified USP7 was incubated with 25 mg of purified
GMPS in a total volume of 25 ml of 50 mM HEPES pH 7.9,
50 mM NaCl, 10% glycerol, 0.1 mM EDTA, 0.1 mM DTT for
1 hour at room temperature. Control samples were also generated
in which USP7 or GMPS were incubated individually. The
mixtures were then diluted to 500 ml in 50 mM HEPES pH 7.9,
5% glycerol, 200 mM NaCl and 0.5 mM EDTA and loaded onto
11.5 ml 10%–20% glycerol gradients formed in the same buffer.
Gradients were subjected to centrifugation in a SW41 rotor at
34,000 rpm for 18 hours at 4uC. Fractions of 500 ml were
collected from the top of each gradient and 30 ml of each fraction
was analyzed on an 8% SDS-polyacrylamide gel. Proteins were
visualized by colloidal blue staining. Aldolase and catalase were
analyzed on identical gradients as size markers.
In vitro histone deubiquitylation assays
Histones for in vitro assays were prepared by acid extraction as
described by Kao and Osley [66]. Briefly, HeLa cells at 70%
confluence were lysed in 10 mM HEPES pH 7.9, 1.5 mM MgCl,
10 mM KCl, 0.5 mM DTT, 1.5 mM PMSF and 1 mM NEM,
then hydrochloric acid was added to a final concentration of
0.2 M. The lysate was incubated on ice for 30 min, then
subjected to centrifugation at 10,0006g for 10 min at 4uC. The
supernatant fraction, containing the histones, was dialyzed
against 0.1 M acetic acid, then against distilled water and store
at 270uC. Prior to use, the histones were diluted to 1 mg/ml and
adjusted to a final concentration of 50 mM HEPES pH 7.9,
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incubated at 37uCw i t h0 . 2mg USP7, with or without 0.1 mg
GMPS (1:1 USP7:GMPS), 0.01 mg GMPS (10:1 USP7:GMPS) or
10 mg GMPS (1:10 USP7:GMPS) as indicated in a 200 ml
reaction. Samples were collected at the indicated times and mixed
with SDS-PAGE loading buffer to stop the reactions. Samples
were analysed by electrophoresis on 15% SDS-polyacrylamide
gels and the levels of ubiquitinated H2B and H2A were visualized
by Western blotting using antibodies against H2B (Upstate
Biochemicals), H2A (Upstate Biochemicals) and ubiquitin
(Sigma).
In vitro p53 deubiquitylation assay
Ubiquitylated p53 was generated by in vitro reactions with
Mdm2. To this end human p53 and Mdm2 were cloned into
pET15b (Novagen), expressed in E.coli and purified by virtue of
the hexahistidine tag using standard metal affinity purification
procedures. P53 was ubiquitylated in vitro as previously described
[67]. Briefly, 5 mg p53 and 5 mg Mdm2 were incubated for 90 min
at 30uC with 500 ng E1 (Calbiochem), 1 mg UbE2D2 (Boston
Biochem), 50 mg ubiquitin (Boston Biochem) in a 200 ml reaction
mixture containing 50 mM Tris pH 7.6, 5 mM MgCl2,2m M
ATP, 2 mM DTT. Ubiquitylation was confirmed by Western blot
analysis of a 10 ml sample using p53 monoclonal antibody
PAb1801 [68] and the remaining mixture was stored at 280uC.
For deubiquitylation assays, 5 mg (10 ml), poly-ubiquitylated p53
was incubated with 0.5 mg USP7 with or without 5 mg of GMPS in
an 10 ml reaction. The samples were collected at the indicated
time points, mixed with SDS-PAGE loading buffer and subjected
to 10% SDS-PAGE. p53 was detected by Western blotting using
p53 antibody PAb1801.
Measurement of ubiquitylated histone levels in vivo
HeLa cells were transfected 3 times during a seven day period
with USP7 siRNA (100 pmols, 200 pmols and 200 pmols,
respectively) or with negative control siRNA against GFP [30]
using Lipofectamine 2000 (Invitrogen). USP7 siRNA sequence
was CCCAAATTATTCCGCGGCAAA as described in Tang et
al 2006 [69]. Cells were then harvested and split into two equal
samples. One sample was used to verify USP7 silencing by
Western blotting using rabbit serum against USP7 [30] and anti-
actin antibody (Calbiochem) as a loading control. The other
sample was used to isolate the histones by acid extraction as
described above and to quantify the levels of ubiquitylated histones
H2B and H2A by Western blotting for these histones as described
above. In each case, the amount of ubiquitylated histone was
determined by normalizing the intensity of this band to that of the
unmodified histone band (set to 1).
Chromatin immunoprecipitation (ChIP) assays performed
on EBV genomes
ChIP assays were performed for GMPS and USP7 in the EBV-
positive, Raji Burkitt’s lymphoma cells as previously described [16]
using anti-USP7 rabbit antibody (Bethyl Laboratories.Inc) or
rabbit antiserum raised against full length recombinant GMPS
purified from insect cells. Rabbit IgG (Santa Cruz) and anti-
EBNA1 R4 rabbit antibody [14] were also used as negative and
positive controls, respectively. Quantitative real-time PCR was
performed with a Platinum SYBR Green qPCR superMix-UDG
(Invitrogen) in a Rotorgene qPCR System (Corbett Research),
using 1/50
th of the ChIP samples or 1/2500
th of DNA samples
prior to immunoprecipitation (input) and the previously described
primer sets for the DS and FR elements and the BZLF1 promoter
region [16]. Values obtained for ChIP samples were normalized to
input samples with the same primer sets. For ChIP assays
involving USP7 depletion, D98/Raji cells [42] were subjected to
three rounds of transfection (every 24 hours) with siRNA against
USP7 or with siRNA against GFP as described above. Samples
were prepared as for the ChIP experiments in Raji cells except
that antibodies against EBNA1, histone H2B (Upstate Biochem-
icals) and mono-ubiquitylated histone H2B (MediMabs Inc,
Montreal) were used. Primer sets used to assess recovery of the
LMP1 promoter region were CAATCAGAAGGGGGAGTGCG
and ACAGCCTTGCCTCACCTGAAC, of Cp promoter region
were AACCTTGTTGGCGGGAGAAG and GGCGAATTAA-
CTGAGCTTGCG, and of oriLyt region were CGTCTTAC-
TGCCCAGCCTACT and AGTGGGAGGGCAGGAAAT. Ex-
periments examining EBNA1 binding to region III used the
primer sets GACCACTGAGGGAGTGTTCCACAG and ACA-
CCGTGCGAAAAGAAGCAC described in Yoshioka et al [36].
EBNA1 ChIP assays performed on transfected plasmids
CNE2Z cells [70] were plated in 6 cm dishes and transfected
with 50 pmols of siRNA against GFP or siRNA against USP7.
siRNA transfections were repeated twice at 24 hour intervals for a
total of 3 rounds of siRNA transfection over 72 hours. Cells were
then moved to 10 cm dishes and transfected with 5 mg of pc3OriP,
pc3OriPEBNA1 or pc3OriPD395–450 and 250 ng pLacZ plasmid
containing LacZ cDNA. 24 hours post-transfection, cells were
fixed with 1% formaldehyde, lysed in RIPA buffer (20 mM Tris
pH 8.0, 150 mM NaCl, 1% NP40, 0.1% Sodium Deoxycholate,
1 mM PMSF) containing protease inhibitor cocktail (Sigma,
P8340) and sonicated briefly to shear the DNA. Clarified lysates
were precleared with Protein A/G beads (Santa Cruz, SC-2003)
prior to immunoprecipitation with EBNA1 R4 antibody and
normal rabbit IgG (Santa Cruz, SC-2345). Protein cross links were
reversed in the immunoprecipitated DNA by incubating at 65uC
for 16 hrs. DNA was purified using QIAquick Gel Extraction Kit
(Qiagen, 28704) and analyzed by quantitative RT-PCR using
LightyCycler 480 DNA SYBR Green I Master (Roche,
04707516001) and a Rotorgene Q-PCR system (Corbett Re-
search). Primers used for DS are as described above. Primers used
for FR and lacZ quantification were CCCGGATACAGATTAG-
GATAGC and TGTTGCCATGGGTAGCATA for FR and
ATATTGAAACCCACGGCATGGTGC and TTTGATGGAC-
CATTTCGGCACAGC for lacZ.
Transcription activation assay
EBNA1 transactivation assays were performed as described
previously [71] with the following modifications. CNE2Z cells
were transfected with siRNA against GFP or USP7 as described
above, then were moved to 10 cm dishes 24 hour prior to
transfection with 2 mg of pFRTKCAT reporter construct (kindly
provided by Bill Sugden) and 180 ng of pc3OriP or pc3Orip
containing expression cassettes for EBNA1 [15] or EBNA1D395–
450. 48 hrs later, cells were harvested and lysed using three rounds
of freezing and thawing. 15 mg of total protein from each sample
was assayed for chloramphenicol acetyltransferase activity using
several reaction times and results from a point in the linear range
was reported.
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